News Article | May 23, 2017
Dr. Kasra Djalayer, Board Certified Physician in Internal Medicine, Obesity Medicine, & Clinical Nutrition with Gifford Medical Center, has joined The Expert Network©, an invitation-only service for distinguished professionals. Dr. Djalayer has been chosen as a Distinguished Doctor™ based on peer reviews and ratings, numerous recognitions, and accomplishments achieved throughout his career. Dr. Djalayer outshines others in his field due to his extensive educational background, career longevity, and numerous awards and recognitions. He attended the University of Complutense in Madrid from which he graduated with his M.D. in 1989. After that, he went on to complete his residency in internal medicine at Yale University’s Griffin Hospital Prevention Research Center. He then undertook four fellowships, including one in Clinical Immunology and Rheumatology from the University of Vermont and one in School Aging and Geriatrics at Stanford University. Dr. Djalayer also holds a Ph.D. in immunology and an M.S. in Clinical Research from the University of London and has completed various post-graduate studies at Harvard University. With nearly 30 years dedicated to medicine, Dr. Djalayer brings a wealth of knowledge to his industry and, in particular, to his areas of expertise, obesity medicine, clinical nutrition, geriatrics, rheumatology, and dementia-related behavioral disorders. When asked why he decided to pursue a career in medicine, Dr. Djalayer said: "My father and grandfather were both doctors, and my father encouraged me to pursue medicine. I wanted to be a doctor because I wanted to help people, to treat them appropriately, with empathy and kindness." Dr. Djalayer is currently a primary care physician practicing with Gifford Medical Center in Randolph, Vermont and is the medical director of Rowan Court Health & Rehabilitation Center, a nursing home in Barre, Vermont. For five consecutive years, he has received both the Patient’s Choice Award and the Compassionate Doctor Recognition Award and is ranked among the top 3% of physicians in the United States. Before joining Gifford Health Care, Inc., Dr. Djalayer worked at several hospitals across New England, including Franklin Regional Hospital and New London Hospital in New Hampshire, and Brattleboro Memorial Hospital in Vermont. Today, his practice covers a vast spectrum of conditions relating to internal and adult medicine as well as rheumatic diseases. From dementia, heartburn, and immunizations, to physicals and challenges with weight loss, his sharp diagnostic abilities have earned him a reputation as one of the best physicians in the United States. Known to his patients as “Dr. DJ”, Dr. Djalayer values the importance of building strong and trusting relationships with each of his clients. He is also famous among both his patients and colleagues for having a photographic memory. Dr. Djalayer is licensed to treat patients in New Hampshire, Vermont, Connecticut, and Missouri, and works hard to provide only the highest quality of care. In 2012, Dr. Djalayer received a letter of appreciation from President Barack Obama, thanking him for his years of commitment and hard work in the healthcare field. To stay involved in his community, he frequently speaks and teaches at field seminars to help mold the next generation of medical professionals. For more information, visit Dr. Djalayer's profile on the Expert Network here: https://expertnetwork.co/members/kasra-djalayer,-md,-phd/2deff4db17af148f The Expert Network© has written this news release with approval and/or contributions from Dr. Kasra Djalayer. The Expert Network© is an invitation-only reputation management service that is dedicated to helping professionals stand out, network, and gain a competitive edge. The Expert Network selects a limited number of professionals based on their individual recognitions and history of personal excellence.
Irmady K.,New York Medical College |
Irmady K.,Griffin Hospital |
Jackman K.A.,New York Medical College |
Jackman K.A.,Florey Institute of Neuroscience and Mental Health |
And 10 more authors.
Journal of Neuroscience | Year: 2014
The neurotrophin receptor p75NTR has been implicated in mediating neuronal apoptosis after injury to the CNS. Despite its frequent induction in pathologic states, there is limited understanding of the mechanisms that regulate p75NTR expression after injury. Here, we show that after focal cerebral ischemia in vivo or oxygen-glucose deprivation in organotypic hippocampal slices or neurons, p75NTR is rapidly induced. A concomitant induction of proNGF, a ligand for p75NTR, is also observed. Induction of this ligand/receptor system is pathologically relevant, as a decrease in apoptosis, after oxygen-glucose deprivation, is observed in hippocampal neurons or slices after delivery of function-blocking antibodies to p75NTR or proNGF and in p75NTR and ngf haploinsufficient slices. Furthermore, a significant decrease in infarct volume was noted in p75NTR -/- mice compared with the wild type. We also investigated the regulatory mechanisms that lead to post-ischemic induction of p75NTR. We demonstrate that induction of p75NTR after ischemic injury is independent of transcription but requires active translation. Basal levels of p75NTR in neurons are maintained in part by the expression of microRNA miR-592, and an inverse correlation is seen between miR-592 and p75NTR levels in the adult brain. After cerebral ischemia, miR-592 levels fall, with a corresponding increase in p75NTR levels. Importantly, overexpression of miR-592 in neurons decreases the level of ischemic injury-induced p75NTR and attenuates activation of pro-apoptotic signaling and cell death. These results identify miR-592 as a key regulator of p75NTR expression and point to a potential therapeutic candidate to limit neuronal apoptosis after ischemic injury. © 2014 the authors.
News Article | November 29, 2016
QUINCY, MA--(Marketwired - November 29, 2016) - NuVal LLC, a company that analyzes the total nutritional value of food products on a scale of 1 to 100 (the higher the score, the better the nutrition), has launched two tools specifically designed to empower consumers with reliable information in order to make more nutritious food choices. The NuVal® Score Search platform provides direct access to the vast NuVal database of scores. The NuScan mobile app allows users to view NuVal Scores anytime, in any store. With these tools, consumers can identify and purchase more nutritious products for themselves and their families. The NuVal Score Search platform provides access to the most scrupulously managed, UPC-specific nutrient database in the world. Over 125,000 national brand and private label products have been scored to date. Created by an international team of leading experts, NuVal is the most comprehensive nutritional scoring system in existence. Over 30 macro and micronutrients are evaluated in the scoring process, as is nutrient density, macronutrient quality, and relevance to disease risk and health outcomes. Using NuVal's mobile app, NuScan, consumers can scan barcodes and see scores instantly. If a product is not found, users can submit product images to NuVal using the app, and will even receive a scoring certificate once processed. In addition, we also wanted to present the opportunity to give the gift of health to family and loved ones. For a limited time only, anyone can purchase a one-year gift subscription for family members or friends to any of the NuVal tools, and this gift subscription can be purchased at 15% of the original price. Launched in 2008, the NuVal Nutritional Scoring System can be found in over 1,600 retail grocery stores throughout the United States. During the last eight years, experts at leading institutions have conducted extensive validation and impact studies, and this research has repeatedly substantiated that the NuVal Scores: With the algorithm and scores fully validated and proven, NuVal is now opening the scoring database to a much broader audience. According to Dr. David Katz, inventor of the ONQI® algorithm that powers the NuVal Scoring System, "NuVal is the most robustly validated nutritional scoring system available. By providing nutrition transparency and encouraging people to "choose a higher number," NuVal empowers shoppers to make healthier decisions. In addition to expert research confirming the NuVal System works, we have heard from people who attribute losing more than 100lbs to NuVal guidance, and trading up their groceries. And now, with these on-line and mobile tools available to the public, coaches and shoppers are able to view the NuVal Scores, choose higher scoring options, and trade up to better nutrition and to better health." To register for a 30-day free trial of NuVal Empower (both tools in one convenient package), go to https://empower.nuvaldata.com/en-US/login.do. Register for Score Search or NuScan individually on the same page. To view the list of relevant published studies, email email@example.com. To learn more about NuVal LLC, visit nuval.com. NuVal LLC is a joint venture formed in 2008 by Topco Associates, LLC, and Griffin Hospital of Derby, Connecticut, a non-profit community hospital and home to the Yale-Griffin Prevention Research Center. Located in Quincy, MA, NuVal licenses its proprietary food scoring system, which is based on ONQI® (Overall Nutrition Quality Index) science, to food retailers across the country.
Gnanaraj J.,Griffin Hospital
Cutaneous and ocular toxicology | Year: 2010
Leuprolide (Lupron) is a synthetic analog of naturally occurring gonadotropin-releasing hormone (GnRH). Leuprolide is used as a hormonal antagonist in the treatment of advanced prostatic cancer, and as hormonal therapy in the treatment of endometriosis. Off-label, it is also used in premenopausal or perimenopausal women with hormone-responsive breast cancer for the purpose of ovarian ablation. Ever since its FDA approval in 1985, many adverse reactions have been reported in association with leuprolide ranging from local skin irritation to severe anaphylactoid reactions. In this case report, we present a case of hypersensitivity vasculitis (serum sickness) in a patient who received leuprolide for his prostate cancer. Serum sickness has never been reported as a side-effect of leuprolide. Our case is the first case of serum sickness associated with leuprolide. We emphasize that physicians using leuprolide should be wary of signs and symptoms of hypersensitivity vasculitis or serum sickness.
Mahmood S.,Griffin Hospital |
Booker I.,University of Connecticut |
Huang J.,University of Connecticut |
Coleman C.I.,University of Connecticut
Journal of Clinical Psychopharmacology | Year: 2013
BACKGROUND: Clinical Antipsychotic Trials of Intervention Effectiveness showed that atypical antipsychotics (AAPs) were associated with significant weight gain and glucose intolerance. A few trials have shown topiramate to reduce weight gain in patients receiving AAPs, although this benefit has not been present in all trials. OBJECTIVE: This study aimed to determine topiramate therapy's impact on weight gain in patients receiving AAPs. DATA SOURCE: A systematic literature search of MEDLINE (1948 to July 8, 2011) and Cochrane CENTRAL (4th Quarter 2011) was conducted. STUDY SELECTION: Eight trials (n = 336 participants) met our inclusion criteria: randomized controlled trial, evaluated topiramate in patients taking AAPs, and reported weight change during the treatment course. DATA EXTRACTION: Two investigators (S.M. and C.I.C.) used a standardized data abstraction tool to independently collect data, with disagreement resolved through discussion. The difference between the mean weight in the topiramate and control groups was calculated as the weighted mean difference with accompanying 95% confidence interval. A random effect model was used for all analyses. DATA SYNTHESIS: Upon meta-analysis, we found that patients receiving topiramate lost weight or had attenuated weight gain compared to control patients (weighted mean difference,-2.83 kg; 95% confidence interval,-4.62 to-1.03). CONCLUSIONS: Our meta-analysis shows that using topiramate can prevent or reduce weight gain associated with AAPs. Copyright © 2013 Lippincott Williams &Wilkins.
Gnanaraj J.F.,Griffin Hospital |
Von Haehling S.,Charité - Medical University of Berlin |
Anker S.D.,Charité - Medical University of Berlin |
Anker S.D.,Center for Clinical and Basic Research |
And 2 more authors.
Kidney International | Year: 2013
Worsening renal function (WRF) during the treatment of acute decompensated heart failure (ADHF) occurs in up to a third of patients and is associated with worse survival. Venous congestion is increasingly being recognized as a key player associated with WRF in ADHF. Understanding the hemodynamic effects of venous congestion and the interplay between venous congestion and other pathophysiological factors such as raised abdominal pressure, endothelial cell activation, anemia/ iron deficiency, sympathetic overactivity, and stimulation of the renin-angiotensin-aldosterone system will help in devising effective management strategies. Early recognition of venous congestion through novel techniques such as bioimpedance measurements and remote monitoring of volume status combined with customized diuretic regimens may prevent venous congestion and perhaps avoid significant WRF. © 2012 International Society of Nephrology.
Bhardwaj S.,Griffin Hospital |
Selvarajah S.,Yale University |
Schneider E.B.,The Surgical Center
Clinical Interventions in Aging | Year: 2013
Statins have demonstrated substantial benefits in supporting cardiovascular health. Older individuals are more likely to experience the well-known muscle-related side effects of statins compared with younger individuals. Elderly females may be especially vulnerable to statin-related muscle disorder. This review will collate and discuss statin-related muscular effects, examine their molecular and genetic basis, and how these apply specifically to elderly women. Developing strategies to reduce the incidence of statin-induced myopathy in older adult women could contribute to a significant reduction in the overall incidence of statin-induced muscle disorder in this vulnerable group of patients. Reducing statin-related muscle disorder would likely improve overall patient compliance, thereby leading to an increase in improved short- and long-term outcomes associated with appropriate use of statins.
Lim L.S.,Griffin Hospital |
Haq N.,Griffin Hospital |
Mahmood S.,Griffin Hospital |
Hoeksema L.,Griffin Hospital
American Journal of Preventive Medicine | Year: 2011
Context: Atherosclerotic cardiovascular diseases, including coronary heart disease (CHD), carotid artery stenosis (CAS), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA), affect millions of U.S. adults and are leading causes of morbidity and mortality. There is some uncertainty regarding the utility of certain screening tests for prevention of cardiovascular morbidity and mortality. Evidence acquisition: Current guidelines and studies pertaining to CHD, CAS, PAD, and AAA screening in the adult population were reviewed. Evidence synthesis: CHD risk can be estimated by the Framingham Risk Score (FRS), which is valuable in identifying high-risk asymptomatic adults who may benefit from preventive treatments. There is moderate certainty that the benefits of screening do not outweigh the harms for individuals with asymptomatic CAS. The potential harms associated with routine PAD screening in asymptomatic adults are also likely to exceed benefits. Ultrasonography is a safe, noninvasive, and reliable screening test used to identify AAAs for treatment in men aged >65 years who have ever smoked. Conclusions: American College of Preventive Medicine (ACPM) recommends CHD risk assessment using the FRS to guide risk-based therapy. ACPM does not recommend routine screening of the general adult population using electrocardiogram, exercise-stress testing, computed tomography scanning, ankle-brachial index, carotid intima medial thickness, or emerging risk factors, including high-sensitivity C-reactive protein (hs-CRP). ACPM does not recommend routine screening of the general adult population for CAS or PAD. ACPM recommends one-time AAA screening in men aged 65-75 years who have ever smoked. Routine AAA screening in women is not recommended. © 2011 American Journal of Preventive Medicine.
Muniraj T.,Yale University |
Muniraj T.,Griffin Hospital |
Barve P.,Yale University
North American Journal of Medical Sciences | Year: 2013
Pancreatic cancer is the tenth most common cancer and the fourth leading cause of cancer deaths in the United States. Surgery remains a cornerstone in the treatment of pancreatic cancer. Unfortunately, the percentage of patients presenting at the resectable stage is minimal. Although computed tomography (CT) scan remains the best modality to stage the tumor for resectability, laparoscopy and laparoscopic ultrasound offers its own advantages. Extended lymphadenectomy, portal vein resection, and arterial reconstruction have also been explored in multiple studies to enhance staging. The traditional pancreaticoduodenectomy (Whipple's procedure) with regional lymphadenectomy is still the standard of care in the surgical treatment of pancreatic cancer.
Griffin Hospital | Date: 2012-10-26
A method for evaluating a diet includes the steps of: inputting information about a plurality of individual foods forming the diet being evaluated into at least one of a computer and a database; evaluating the diet by measuring the quality of the individual foods forming the diet and compiling scores for each of said measured individual foods to generate an overall score for the diet, wherein the evaluating and compiling step is performed by the computer; and providing information to an individual about overall healthiness of the diet being evaluated.